1 / 46

CHARM Program: 3 Component trials comparing candesartan with placebo

breena
Download Presentation

CHARM Program: 3 Component trials comparing candesartan with placebo

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. CHARM Program: 3 Component trials comparing candesartan with placebo

    2. CHARM Program: Baseline characteristics

    3. CHARM Program: Baseline medications

    4. CHARM-Overall: CV death and non-CV death

    5. CHARM Program: Reduction in mortality and morbidity

    6. CHARM Program: Reduction in CHF hospitalization

    7. CHARM-Preserved: Hospital admissions for CHF

    8. CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis

    9. CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis (cont’d)

    10. CHARM-Added: Effect of combined ACE inhibitor/ ?-blocker/AT1-receptor blocker

    11. CHARM-Overall: Drug discontinuations for adverse events

    12. CHARM: Clinical implications

    13. CHARM-Overall: Reduction in new-onset diabetes

    14. CHARM: Impact of treatment

    15. HF with preserved LV systolic function in the elderly: Impact on survival

    16. CHARM-Preserved: CV death or CHF hospitalization

    17. CHARM-Preserved: Primary and secondary outcomes

    18. CHARM-Preserved: Clinical implications

    19. VALIANT: Design

    20. VALIANT: Concomitant medications

    21. VALIANT: Treatments show similar effect on outcome

    22. VALIANT: Clinical implications

    23. VALIANT: Effect of treatment on mortality—Subgroup analysis

    24. RESOLVD: Comparative impact of ACE inhibitor, ARB, and ?-blocker alone or combined on LVEF

    25. Differences in dosing among ARB trials

    26. Survival studies of ?-blockade in HF

    27. ?-Blockers improve survival in diabetic patients with HF: A meta-analysis

    28. MERIT-HF: ?-Blockade improves survival in CHF

    29. MERIT-HF: ?-Blockade improves survival in post-MI patients with HF

    30. MERIT-HF: Subgroup analysis in post-MI patients with HF (LVEF <25%)

    31. SOLVD: Heart rate predicts progression of asymptomatic LV dysfunction

    32. MERIT-HF: Effect of ?-blockade on heart rate

    33. MERIT-HF: ?-Blockade decreases mortality and hospitalization independent of resting heart rate

    34. CHRISTMAS: Design

    35. CHRISTMAS: Trial profile

    36. CHRISTMAS: Change in LVEF according to number of segments affected by myocardial hibernation

    37. COMET: Trial profile

    38. COMET: All-cause mortality

    39. COMET: Heart rate at each visit

    40. COMET: Blood pressure

    41. ?-Blocker HF trials: Mortality results

    42. Mortality rates in perspective CIBIS-II, MERIT-HF, COMET

    43. Immediate-release vs sustained release metoprolol: Significant pharmacokinetic differences

    44. COMET: Clinical implications

    45. Comparison of ?-blocker effects in major HF trials

    46. Not all ?-blockers are the same

More Related